Tsuchimoto Kim R 的 Form 4/A 修正申報
修正Monopar Therapeutics（MNPR），2026/8/28 申報
- 申報編號
- 0001437749-26-029235
- 申報時間
- 2026/8/28 20:18 ET
- 交易日
- 2026/8/26
- 申報延遲
- 2 天
- 10b5-1 計畫
- 有勾選
- 原始申報日
- 2026/8/27
這份申報列了 8 筆非衍生性交易、2 筆衍生性交易。公開市場賣出合計 $45.6 萬。交易後 2 天申報。
這份修正申報取代了 0001437749-26-029116（2026/8/27 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Tsuchimoto Kim RCIK 0001333516 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/8/26 | Common Stock | M行使選擇權取得 | +2,055 | $30.00 | +$61,650 | 2,055 | 直接 | |
| 2026/8/26 | Common Stock | M行使選擇權取得 | +2,035 | $14.00 | +$28,490 | 4,090 | 直接 | |
| 2026/8/26 | Common Stock | S賣出處分 | −485 | $108.83F4 | −$52,782.55 | 3,605 | 直接 | |
| 2026/8/26 | Common Stock | S賣出處分 | −615 | $109.56F5 | −$67,379.4 | 2,990 | 直接 | |
| 2026/8/26 | Common Stock | S賣出處分 | −700 | $110.65F6 | −$77,455 | 2,290 | 直接 | |
| 2026/8/26 | Common Stock | S賣出處分 | −1,098 | $111.84F7 | −$122,800.32 | 1,192 | 直接 | |
| 2026/8/26 | Common Stock | S賣出處分 | −602 | $112.93F8 | −$67,983.86 | 590 | 直接 | |
| 2026/8/26 | Common Stock | S賣出處分 | −590 | $113.84F9 | −$67,165.6 | 0 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/8/26 | Common Stock | M行使選擇權取得 | +2,055 | $0.00 | $0 | 6,165 | 直接 | |
| 2026/8/26 | Common Stock | M行使選擇權取得 | +2,035 | $0.00 | $0 | 8,140 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
- F2
On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
- F3
On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F10
Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
備註
On August 27, 2026, the reporting person filed a Form 4, which inadvertently omitted two option exercises that were made prior to the reporting person's sale of shares of common stock. Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan.